Indeed, a phase I trial of a defucosylated humanized anti-CC chemokine receptor 4 (CCR4) antibody, KW-0761, in relapsed CCR4-positive adult T-cell leukemia–lymphoma or other peripheral T-cell lymphomas revealed that the antibody had antilymphoma activity even at a low dose of 0.01 mg/kg (Niwa et al. 2004). Here, CCR4 is linked to lymphoma.